title: Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
abstract: Ceftaroline has been approved for acute bacterial skin infections and community-acquired bacterial pneumonia. Limited clinical experience exists for use outside these indications. The objective of this study was to describe the outcomes of patients treated with ceftaroline for various infections. Retrospective analyses of patients receiving ceftaroline ≥72 h from 2011 to 2013 were included. Clinical and microbiological outcomes were analyzed. Clinical success was defined as resolution of all signs and symptoms of infection with no further need for escalation while on ceftaroline treatment during hospitalization. A total of 527 patients received ceftaroline, and 67% were treated for off-label indications. Twenty-eight percent (148/527) of patients had bacteremia. Most patients (80%) were initiated on ceftaroline after receipt of another antimicrobial, with 48% citing disease progression as a reason for switching. The median duration of ceftaroline treatment was 6 days, with an interquartile range of 4 to 9 days. A total of 327 (62%) patients were culture positive, and the most prevalent pathogen was Staphylococcus aureus, with a frequency of 83% (271/327). Of these patients, 88.9% (241/271) were infected with methicillin-resistant S. aureus (MRSA). Clinically, 88% (426/484) achieved clinical success and hospital mortality was seen in 8% (40/527). While on ceftaroline, adverse events were experienced in 8% (41/527) of the patients and 9% (28/307) were readmitted within 30 days after discharge for the same infection. Patients treated with ceftaroline for both FDA-approved and off-label infections had favorable outcomes. Further research is necessary to further describe the role of ceftaroline in a variety of infections and its impact on patient outcomes.
authors.affiliation: Anti-Infective Research Laboratory, Pharmacy Practice Department, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
authors.forename: Anthony M
authors.initials: AM
authors.lastname: Casapao
authors.forename: Susan L
authors.initials: SL
authors.lastname: Davis
authors.forename: Viktorija O
authors.initials: VO
authors.lastname: Barr
authors.forename: Kenneth P
authors.initials: KP
authors.lastname: Klinker
authors.forename: Debra A
authors.initials: DA
authors.lastname: Goff
authors.forename: Katie E
authors.initials: KE
authors.lastname: Barber
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
authors.forename: Ryan P
authors.initials: RP
authors.lastname: Mynatt
authors.forename: Leah M
authors.initials: LM
authors.lastname: Molloy
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D012189:Retrospective Studies; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline